/
Hematology
Sickle Cell Disease
74
Pipeline Programs↗
129
Active Trials↗
59
Companies Involved↗
Sickle Cell Disease is a moderately active landscape with 74 programs across 59 companies. The most active players are Sanofi, Novartis, Agios Pharmaceuticals, Inc.. 14 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical12
Phase 113
Phase 235
Phase 314
Approved
No programs
Analysis
Modality Breakdown
80%
Small molecule
52 of 65 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 65 classified programs, each share of the total. Modality classified for 96% of 74 pipeline programs.
Analysis
Trial Status
348
clinical trials
Completed141 · 41%
Recruiting69 · 20%
Terminated50 · 14%
Active, not recruiting39 · 11%
Not yet recruiting20 · 6%
Withdrawn13 · 4%
Other16 · 5%
Clinical Trials
Trial Activity
348 trials
Page 1 of 24
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)